Monotherapy With Anti-CD70 Antibody Causes Long-Term Mouse Cardiac Allograft Acceptance With Induction of Tolerogenic Dendritic Cells

Jing Zhao1,2,3, Weitao Que1, Xiaoxiao Du4, Masayuki Fujino1,5, Naotsugu Ichimaru2, Hisashi Ueta6, Nobuko Tokuda6, Wen-zhi Guo4, Piotr Zabrocki7*, Hans de Haard7, Norio Nonomura2 and Xiao-Kang Li1,4*

1 Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan, 2 Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Osaka, Japan, 3 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China, 4 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 5 AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan, 6 Department of Anatomy (Macro), Dokkyo Medical University, Tochigi, Japan, 7 argenx BV, Zwijnaarde, Belgium

Allograft rejection has been an obstacle for the long-term survival of patients. CD70, a tumor necrosis factor (TNF) family member critically expressed on antigen-presenting cells and strongly but transiently up-regulated during lymphocyte activation, represents an important co-stimulatory molecule that induces effective T cell responses. We used a mouse heterotopic cardiac transplantation model to evaluate the effects of monotherapy with the antibody targeting mouse CD70 (FR70) on transplantation tolerance and its immunoregulatory activity. FR70-treated C3H recipient mice permanently accepted B6 fully mismatched cardiac allografts. Consistent with the graft survival, the infiltration of CD8+ T cells in the graft was reduced, dendritic cells were differentiated into a tolerogenic status, and the number of regulatory T cells was elevated both in the graft and the recipient’s spleen. In addition, naïve C3H given an adoptive transfer of spleen cells from the primary recipients with FR70 treatment accepted a heart graft from a matching B6 donor but not third-party BALB/c mice. Our findings show that treatment with FR70 induced regulatory cells and inhibited cytotoxic T cell proliferation, which led to long-term acceptance of mouse cardiac allografts. These findings highlight the potential role of anti-CD70 antibodies as a clinically effective treatment for allograft rejection.

Keywords: allograft, CD70, dendritic cell, regulatory T cell, rejection, tolerance
INTRODUCTION

Significant breakthroughs have been made in regard to the short-term graft survival over the last few decades, but improving the long-term graft survival still remains a challenge. Innovative treatments preventing transplant rejection, in particular, is a significant unmet need (1). Previous studies have shown that CD70 blockade can inhibit the clonal expansion of CD8+ T cells and reduce the generation of memory CD8+ T cells (2, 3). Anti-CD70 monoclonal antibody (mAb) administered in combination with an anti-CD154/LFA-1 mAbs regimen during primary transplantation alleviated the accelerated rejection mediated by memory T cells (4). Furthermore, in a memory T cell-based adoptive mouse model, the combination of four antibodies against CD44, CD70, CD40L, and LFA-1 significantly inhibited the proliferation of memory T cells ex vivo but failed to induce long-lived heart allograft acceptance in vivo (5).

Recently, the role of suppressive signaling from dendritic cells (DCs) inducing graft tolerance has been emphasized (6, 7). The CD70 levels in mice are transiently up-regulated during lymphocyte activation, making it difficult to track its expression on DCs (8, 9). Nevertheless, CD70 expressed on DCs during their maturation plays a critical role in immunogenicity while also playing a pivotal role in priming T cells and in the function of regulatory T cells (10). Indeed, the transgenic expression of CD70 on resting DCs is sufficient to provide CD8+ T cells with immunity, whereas its blockade averts CD8+ T cell priming in lymphocytic choriomeningitis virus infection (8, 9, 11, 12). In addition, anti-CD70 treatment was able to suppress Th17-cell induced inflammatory diseases, including experimental autoimmune encephalomyelitis (13). In cancer vaccine therapy, blocking CD70 markedly reduced the generation of alloantigen-specific Tregs, and ensuring the long-term acceptance of a cardiac allograft in mice.

MATERIALS AND METHODS

Animals and Mouse Heterotopic Cardiac Transplantation Model

All animals in this experiment were used in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Male C57BL/6NCrSlc (B6, H-2b) mice, C3H/HeNSlc (C3H, H-2k) mice, BALB/cCrSlc (BALB/c, H-2d) mice, 8–12 weeks old, were purchased from SLC (Shizuoka, Japan). All of the mice were kept under specific-pathogen-free conditions. The heart transplantation procedures were conducted as previously described (21). The experimental protocol was approved by the Committee on the Ethics of Animal Experiments of the National Research Institute for Child Health and Development, Tokyo, Japan.

Reagents

Anti-mouse CD70 antibody (mouse IgG2a, FR70) and the isotype control were supplied by argenx BV (Zwijnaarde, Belgium).

Treatment Protocol

Mice received heterotopic cardiac transplantation and were separated into three groups: the syngeneic group, control group, and treatment group. In the treatment group, mice were treated with intraperitoneal (i.p.) injection of 500 µg FR70 immediately after the surgery and with three half-dose (250 µg/mouse, i.p.) injections in the following 5 days. The control group was treated with an isotype control IgG. The cardiac graft survival was determined by the daily palpation of the recipient’s abdomen. An impalpable heart beat was considered graft rejection and confirmed visually by laparotomy.

Adoptive Transfer Studies

Spleen cells (SPCs, 5 × 107) from primary recipient C3H mice bearing an accepted B6 cardiac allograft on post-operative day (POD) 60 and 100 were adoptively transferred to secondary recipient C3H mice. The secondary recipient mice underwent transplantation with B6 (donor-type) or BALB/c (third-party) cardiac grafts immediately after the splenocytes had been injected.

Isolation of Graft-Infiltrating Lymphocytes and Flow Cytometry Analysis

Graft-infiltrating lymphocytes (GILs) were isolated from the cardiac graft, and a flow cytometry (FCM) analysis was performed, as previously described (22–24). Spleen tissue and GILs were stained with fluorochrome-conjugated anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD25 (PC61), anti-CD44 (IM7) and anti-CD62L (MEL-14) mAb; for the DC analysis, cells were stained with anti-CD11b (M1-70), lymphocyte (CTL) proliferation despite the presence of alloantigens, and thus inducing the long-term acceptance of a cardiac allograft in mice.

Abbreviations:

APCs, antigen-presenting cells; CTL, cytotoxic T lymphocyte; DCs, dendritic cells; FCM, flow cytometry; GILs, graft-infiltrating lymphocytes; H&E, hematoxylin and eosin; iPSCs, induced pluripotent stem cells; IFN-γ, interferon-γ; IHC, immunohistochemistry; MHC, major histocompatibility complex; MST, mean survival time; POD, post-operative day; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SPCs, spleen cells; TNF, tumor necrosis factor; Tregs, regulatory T cells; TolDCs, tolerogenic DCs.
RESULTS

Treatment With FR70 Induces Long-Term Acceptance of Mouse Cardiac Allografts

Animals with grafted cardiac transplants received an isotype control antibody (control) or FR70 (treatment) (Figure 1A). As shown in Figure 1B and Table 1, the IgG-treatment control C3H mice rejected B6 cardiac allografts, with a mean survival time (MST) of 8 days, while the administration of FR70 induced long-term cardiac allograft acceptance, with an MST of about 100 days (p < 0.0001). Grafts from the treatment group recipients showed a completely preserved cardiac structure compared to the control group, with less interstitial infiltration and a similar structure compared to syngeneic recipients with grafts from C3H donors (Figure 1C).

FR70 Administration Reduces the Number of Cytotoxic T Lymphocytes and Down-Regulates the Expression of CTL-Related Genes in GILs and in the Spleen

GILs from the control group and FR70-treated group were analyzed by FCM on POD7 (Figure 2). GILs from the treatment group had a significantly smaller population of cytotoxic CD8+ T cells (but not CD4+ T cells) than the control group (Figure 2A). In addition, a more detailed immunohistochemical (IHC) analysis of the grafts confirmed that there were fewer focal infiltrations of CD8+ lymphocytes in the treatment group than in the control group (Figure 2B).

Similarly, SPCs from the syngeneic transplant group, control group and treatment group were analyzed by FCM on POD7. In addition, for the treatment group, we also performed an analysis of the SPCs from POD60 and 100. Animals treated with a control antibody had increased numbers of CD8+ cells compared to the syngeneic group (not shown), while the administration of FR70 reduced the number of CD8+ cells (Figure 2A). The effect was even more pronounced in SPCs in comparison to GILs (30 and 54% decrease in the number of CD8+ in SPCs from treatment recipients. The expression of CD8+ cells in the treatment group than in the control group (Figure 2A).

For the CTL levels checked by FCM in the spleen, the expression of genes related to CTLs, such as perforin, interferon-γ and granzyme B, was evaluated by quantitative RT-PCR at POD7, 60 and 100 in SPCs from treatment recipients. The expression of perforin was significantly increased in the spleen in the control group mice, but treatment with FR70 stabilized the expression of this gene to the level observed in the syngeneic model (not shown), with long-lasting efficacy (Figure 2C). The expression of interferon-γ (IFN-γ), a cytokine activating the immune response and produced by, among others, CTLs, was also reduced to some extent after treatment with FR70 (p > 0.05), but there was no such effect found for granzyme B expression, possibly due to the increased number of CD4+ cells in the spleen. In contrast to the
data obtained from the spleen, the expression of the CTL-related genes perforin and granzyme B as well as interferon-
g was not significantly reduced after the treatment with FR70 (Figure 2C). This confirms the data obtained from the analysis on CTL levels in GILs and spleen showing most dramatic changes in the spleen and to a lesser extent in GILs.

In previous studies, memory T cells have been reported to be affected by the treatment with FR70 in a cardiac transplant model in presensitized mice. We also performed FCM analysis of effector and central memory cells among CD4+ and CD8+ in GILs and SPCs after the treatment with FR70, however, none of the memory T cell populations were found to be significantly decreased in the GILs and SPCs after the treatment (Supplementary Figure 1). These results may emphasize an important role of activated memory T cells in more aggressive models with presensitization to the graft donor antigens and less impact of these T cell populations in less acute mouse models without presensitization.

FIGURE 1 | Anti-CD70 antibody (FR70) treatment induced long-term acceptance of mouse cardiac grafts. (A) FR70 (500 µg) was intraperitoneally (i.p.) injected into C3H recipient mice immediately after heterotopic cardiac transplantation, and in the following 5 days, three additional half-dose (250 µg, i.p.) FR70 injections were performed. (B) The graft survival data are presented in detail. C3H recipients that underwent transplantation of a heart from B6 mice were either not treated or treated with FR70 (n = 18 mice for not treated group, n = 25 mice for treated group, mean ± SEM, pooled from five independent experiments). The mean survival time (MST) is shown in Table 1. A statistical evaluation of the graft survival was performed using Kaplan–Meier curves and compared using log-rank tests, ***p < 0.0001. (C) Histologic studies of harvested cardiac grafts were performed with hematoxylin–eosin (HE) staining. Syngeneic B6 heart (Syngeneic), isotype control-treated B6 cardiac allograft (Allo) and FR70-treated B6 cardiac allograft (Allo + FR70) on POD7 are shown (n = 3 mice/group, scale bars: 200 µm).

TABLE 1 | The mean survival time data from the mouse cardiac grafts experiments after treatment with the isotype control or FR70.

| Group     | n   | Graft survival days | Mean ± SEM | p value to control |
|-----------|-----|---------------------|------------|-------------------|
| Control   | 18  | 7 × 2, 8 × 12, 9 × 4 | 8.1 ± 0.1  | N/A               |
| Treatment | 25  | 38, 41, >100 × 23   | 95.1 ± 3.3 | <0.001            |

A statistical evaluation of the graft survival was performed using Kaplan–Meier curves with a comparison using log-rank tests, and p < 0.05 was considered significant.
spleen at POD7 (Figure 3B), and it also increased slightly in graft compared with the control group. The observed effects appeared to be long-lasting for the PD-L1 and CD86 expression in spleen, since the same significant change in the expression was still present at POD100 (Figure 3B). In agreement with these results, we found that the mRNA levels of CD40, CD80, and CD86 and MHC class II antigens were significantly lower in GILs and/or SPCs isolated from the FR70-treated group at POD7 and/or POD60 and 100 than in those isolated from the isotype control group at POD7 (Figure 3C). Similar to the results from FCM analysis, mRNA levels of PD-L1 were significantly increased in animals treated with FR70 in GILs and SPCs (Figure 3C).

Furthermore, an analysis of the gene expression of regulatory proteins, such as heme oxygenase-1 (HO-1) and indoleamine 2,3-dioxygenase (IDO1) (28–32), showed a significant up-regulation of HO-1 expression in GILs and SPCs and IDO1 in GILs from recipients treated with FR70 (Figure 3C). Similar to the results from FCM analysis, mRNA levels of PD-L1 were significantly increased in animals treated with FR70 in GILs and SPCs (Figure 3C).

To confirm that TolDCs developed during FR70 treatment, we tested the effects of FR70 treatment on the gene expression of other TolDC-related proteins, such as iNOS, IL-1β, IL-6, IL-12α and IL-12β (16, 33–36). A gene expression analysis using quantitative RT-PCR revealed that all of these genes, in particular IL-6 and IL-12β, were significantly down-regulated in GILs and/or SPCs in mice treated with FR70 compared with the isotype control group (Figure 3D), which indicates that blocking CD70 leads to an increase in the number of TolDCs in spleen and grafts.

Treatment With FR70 Leads to the Generation of Tregs

As reported previously, DCs are able to regulate T cell functions (12), and Tregs are a key controller of immunological tolerance (37). Recruitment of Tregs for the induction of transplant tolerance has been considered an attractive strategy for
FIGURE 3 | Continued
attenuating the immune response and preventing transplant rejection. We suspected that Tregs were also involved in the CD70 inhibition-mediated prolonged allograft survival. To prove this, we used FCM to determine the number of CD25 and Foxp3 double-positive cells among GILs and SPCs collected from the FR70-treated recipients on POD7, 60 and 100 and the control group on POD7.

As shown in Figure 4A, the population of CD25+Foxp3+ cells among the CD4+ GILs in the FR70-treated group was increased compared with the isotype control recipients (statistically significant increase at POD7 and 60). A similar effect was observed in the spleen cell population (an increase up to 41 and 23% in case of GILs and SPCs at POD60, respectively). The effect gradually declined, and the Tregs count reached the same value as that observed in the control group at POD100 (Figure 4A). We also evaluated the mRNA expression for Foxp3 using quantitative RT-PCR. The Foxp3 mRNA levels were significantly increased in GILs but less evident in SPCs in the FR70-treated group compared to the isotype control group, and the effect was long-lasting in case of GILs, since increased Foxp3 expression was still detectable at POD100 (Figure 4B). These data were consistent with the FCM

---

**Figure 4** | The Treg cell number and the related mRNA expression were significantly increased in graft and spleen of the FR70-treated recipients. (A) GILs were collected from control (Allo) and FR70-treated groups on POD7, and spleens were harvested from the control group (Allo) on POD7 and the FR70-treated group on POD7 and 100 for FCM. Gating strategy is shown in Supplementary Figure 3A (n = 3-5 mice/group, mean ± SEM, pooled from two independent experiments). Statistical analysis was determined by Student’s t-test, one-way ANOVA, and Tukey’s test. *p < 0.05, **p < 0.01. (B) The median fluorescence intensity (MFI) in CD11c and CD11b double-positive cells in graft and spleen was estimated for cells stained with anti-CD40, CD80, CD86, IA/IE, or PD-L1 antibodies and detected by FCM (Grafts: n = 2 mice/control group; n = 3 mice/FR70-treated group; Spleens: n = 4 mice for isotype control group; n = 5 mice/FR70-treated group POD7 and POD100, mean ± SEM, pooled from two independent experiments). Statistical analysis was determined by Student’s t-test, one-way ANOVA, and Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001. (C, D) Grafts and spleens were collected from the control and FR70-treated groups on POD7. In addition, GILs and SPCs from the FR70-treated groups were collected at POD60 and 100. The mRNA expression was quantified by quantitative RT-PCR (Grafts: n = 4 mice/control group; n = 4 mice/FR70-treated POD7 group; n = 5 mice/FR70-treated POD60 group; n = 5 mice/FR70-treated POD100 group; Spleens: n = 4 mice/isotype control group; n = 5 mice/FR70-treated POD7, 60 and 100 groups, mean ± SEM, pooled from two independent experiments with three biological replicates). Statistical analysis was determined by one-way ANOVA and Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
results, where we also observed a stronger induction of Tregs in GILs.

Tregs produce inhibitory cytokines, such as TGF-β and IL-10, and TGF-β is involved in the differentiation of Tregs from CD4+ cells. We evaluated the TGF-β and IL-10 gene expression at the mRNA level in GILs and SPCs to investigate the effects of blocking CD70 on the expression of these cytokines and found that IL-10 expression significantly increased in GILs and SPCs during treatment (POD7), but only a limited and insignificant increase was observed in case of TGF-β (Figure 4B and not shown). The mRNA expression of IL-10 clearly decreased after treatment was stopped (POD60 and 100), which was in agreement with the observed decrease in the number of Tregs in animals treated with FR70.

Taken together, our results show that treatment with anti-CD70 antibody leads to CD4+CD25+Foxp3+ Tregs’ expansion, in particular in grafts, which may have a critical impact on the immune response after transplantation.

**TolDCs and Tregs Generated by Treatment With FR70 Are Actively Immunosuppressive**

In order to confirm that induced TolDCs and Tregs were directly involved in the mechanism of tolerance, an in vivo adoptive transfer study was performed. As shown in Figure 5 and Table 2, the secondary naïve C3H recipients underwent an adoptive transfer of SPCs isolated from mice (the primary recipients treated with FR70) at POD60 and 100, and they showed a survival rate similar to that observed in the treatment group, with MSTs of 100 and 92 days, respectively. In contrast, secondary C3H recipients given an adoptive transfer of SPCs from naïve C3H mice (naïve AT control) rejected the B6 hearts. Furthermore, all naïve C3H recipients with an adoptive transfer of SPCs isolated from FR70-treated primary recipients at POD60 and 100 acutely rejected third-party (BALB/c) mouse cardiac allografts. These data indicate that the administration of FR70 generated regulatory cells in the recipients that were donor-specific.

Interestingly, the secondary naïve C3H recipients receiving SPCs isolated at POD60 from the primary recipients treated with FR70 showed no incidents of graft rejection, whereas in those with transplanted SPCs isolated at POD100 we observed a gradual loss of grafts. These results suggested that there were occurring changes in time in the potency of SPCs from FR70 treated animals to mediate immunotolerance in secondary recipients. In order to identify factors important for maintenance of the immunotolerogenic properties of SPCs observed in our model on POD60 and POD100, we categorized all data from our analysis of the immune cells in spleen based on the post-treatment timeline (POD7, POD60 and POD100) (Table 3). In animals treated with FR70 there were differences in the number of lymphocytes and DCs, but also qualitative changes in DCs on POD7, 60 and 100. The observed decrease in the number of CTLs did not explain the difference in the tolerogenic properties of SPCs at POD60 and 100, since the decrease was observed to a similar extent at all three PODs. In contrast, a significant increase in the number of Tregs was observed at POD7 and 60, but Treg levels decreased at POD100. Moreover, analysis of DCs showed a significant increase in numbers of DCs only just after the treatment (POD7), but the remaining DCs at POD60 and 100 showed

![Figure 5](image3)

**FIGURE 5** Tolerance induced by FR70 resulted in the acceptance of secondary donor-type cardiac grafts after adoptive splenocyte transfer. The splenocytes harvested at POD60 and 100 from the C3H recipients bearing B6 grafts were adoptively transferred into naïve C3H mice, which were then given B6 (donor type) or BALB/c (third party) cardiac allografts. The graft survival after adoptive transfer of splenocytes is shown (n = 7 mice for naïve AT control group, n = 3 mice for 60 days-AT-D_type group, n = 8 mice for 100 days-AT-D_type group, n = 3 mice for 60 days-AT-Third party group, n = 7 mice for 100 days-AT-Third party group, pooled from two independent experiments). Table 2 shows the detailed graft survival data. A statistical evaluation of the graft survival was performed using Kaplan–Meier curves with a comparison using log-rank tests. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

**TABLE 2** The detailed graft survival data after adoptive transfer of splenocytes.

| Group                        | n  | Graft survival days | Mean ± SEM | p value to naïve AT control | p value to 60days-AT | p value to 100days-AT |
|------------------------------|----|-------------------|-----------|----------------------------|----------------------|----------------------|
| Naïve AT control             | 7  | 9 × 3, 10 × 2, 14, 15 | 10.9 ± 1.0 | N/A                        | 0.0070               | <0.0001              |
| 60 days-AT-D_type            | 3  | 100 × 3           | 100 ± 0.0 | 0.0070                     | NS                   | NS                   |
| 100 days-AT-D_type           | 8  | 43, 51, 80, 88 × 3, 100 × 2 | 92.8 ± 2.9 | <0.0001                  | NS                   | N/A                  |
| (60 days)-AT-Third party     | 3  | 7 × 3             | 7.0 ± 0.0 | 0.0027                     | 0.0253               | NS                   |
| (100 days)-AT-Third party    | 7  | 7 × 7             | 7.0 ± 0.0 | 0.0003                     | NS                   | 0.0002               |

*A statistical evaluation of the graft survival was performed using Kaplan–Meier curves with a comparison using log-rank tests, and p < 0.05 was considered significant.
tolerogenic properties with the expression pattern characteristic for TolDCs. More TolDC-related changes in DCs were observed at POD60 than at POD100 (e.g. increased HO-1 and decreased iNOS and CD40 expression). Therefore, quantitative and qualitative differences in Tregs and DCs correlate with a stronger tolerogenic potential of SPCs harvested at POD60 than POD100 to support graft survival after secondary transplant. Nevertheless, there were also observed long-lasting significant changes characteristic for TolDCs and tolerogenic microenvironment (decreased CD80/CD86, increased PD-L1 expression and decreased expression of IL-6 and IL-12 cytokines) at POD7, 60 and 100, which explains the ability of SPCs harvested even at POD100 to support a relatively long-term acceptance of allograft in secondary recipients. One would assume that the observed changes in Treg and DC numbers could potentially affect survival of grafts in the primary recipient group, but only very few mice treated with FR70 rejected graft during our study (Table 1). Therefore, we conclude that both quantitative and qualitative changes in regulatory cells and microenvironment combined with the reduced number of CTLs were sufficient to maintain a long-term graft tolerance also in the primary recipients (Supplementary Figure 4).

**DISCUSSION**

The role of CD70 in cardiac transplant acceptance has already been reported (2), but the details of the mechanism underlying this phenomenon still remain to be elucidated. Here we used the mouse model of cardiac grafting without presensitization to dissect the mode of action of anti-CD70 monotherapy in preventing graft rejection (Supplementary Figure 4). CTLs and memory T cells play a critical role in cardiac allograft rejection (1, 6, 22, 38). The monotherapy with anti-CD70 antibody induced allograft acceptance by decreasing CTLs to numbers observed in the syngeneic mouse model but did not affect CD4+ cells, in agreement with the previously published data (2). Moreover, the therapy did not cause depletion of memory T cells, suggesting that the memory T cells are not involved in the primary response in our model. Interestingly, the models of viral infections in CD70−/− mice showed that the lack of CD70 expression mainly affects effector CD8+ but not CD4+ nor memory T cells (39), supporting our conclusions that FR70 monotherapy also mainly affected the CTLs.

The observed discrepancy in the response to memory T cells may also be partially due to using mouse strains with a different genetic background or the presensitization increasing the severity of the immune response. For example, the memory T cells involved in cardiac rejection in more acute models with presensitization are able to overcome the benefit of treatment with antibodies (5). The treatment with different antibody combinations, including anti-CD70, showed a dramatic reduction in the number of both CD4+ and CD8+ memory T cells and prolonged graft survival (4, 5, 39) but were not able to promote the long-term acceptance.

Of note, we used mouse IgG2 FR70 antibody in contrast to the rat FR70 used in other studies, which may also have had an impact on the immune response in the previously described models (5) and might explain some contradictions in the efficacy of FR70 in different studies. The observed effects on CTLs may be due in part to direct targeting of these cells by FR70, which can trigger cytotoxicity and reduce the number of CTLs. Nevertheless, the graft acceptance was durable (lasting >100 days after 1 week of treatment) and cannot be attributed solely to the effector function of FR70. Furthermore, an adoptive transfer of splenocytes harvested 100 days after the treatment with FR70 into the secondary naïve recipient resulted in allograft acceptance. Therefore, it is evident that Tregs and TolDCs from FR70-treated recipients, but not FR70 antibody itself, are responsible for this effect. Consequently, the FR70 works through preventing activation of lymphocytes and keeping the cells in immature tolerogenic state further affecting the immune response, rather than only depleting particular populations of the cells expressing CD70 (Supplementary Figure 4).

DCs play a key role in determining the balance between immunity and tolerance, depending on their status. Different strategies for inducing TolDCs in order to promote allograft acceptance or increase immune tolerance are currently being explored (19, 40). We herein report the therapeutic potential of inducing TolDCs via CD70 blocking in order to achieve long-term allograft acceptance. The expression analysis of DC markers showed a lower expression of the co-stimulatory molecules and MHC II on DCs in SPCs and GILs from the FR70-treated group recipients in comparison with the control group. In addition, the expression of pro-inflammatory cytokines produced by conventional DCs involved in

---

**Table 3** Statistically significant quantitative and qualitative changes in the immune response in spleen of recipients after FR70 treatment on POD7, 60 and 100 in comparison to POD7 of the control recipients.

| Compartment | POD7 | POD60 | POD100 |
|-------------|------|-------|--------|
| **Spleen**  |      |       |        |
| T cell-related |      |       |        |
| CTLs        | ↓ CTL number | ↓ CTL number | ↓ CTL number |
|             | ↓ perforin mRNA | ↓ perforin mRNA | ↓ perforin mRNA |
| Tregs       | ↑ Treg number | ↑ Treg number |        |
|             | ↑ IL-10 mRNA   |        |        |
| **DC-related** |      |       |        |
| TolDCs      | ↑ DC number | Not available | ↑ HO-1 mRNA |
|             | ↓ CD40 mRNA/protein | ↓ iNOS mRNA | ↓ CD80 mRNA |
|             | ↓ CD80 mRNA/protein | ↓ CD86 mRNA | ↓ CD86 mRNA |
|             | ↑ PD-L1 protein | Not available | ↑ PD-L1 protein |
| **Cytokines** |      |       |        |
|             | ↓ IL-1β mRNA |        |        |
|             | ↓ IL-12β mRNA | ↓ IL-12β mRNA | ↓ IL-12β mRNA |
|             | ↓ IL-6 mRNA   | ↓ IL-6 mRNA | ↓ IL-6 mRNA |

Cells isolated from spleen on POD60 and 100 were used in a secondary transplant experiment. Long-term tolerogenic effects observed in the primary recipients were caused by time-dependent quantitative and qualitative changes in regulatory cells, which also translated in the tolerogenic memory effect and acceptance of grafts in the secondary transplant recipients; ↓ decreased levels, ↑ increased levels.
allograft rejection, in particular IL-6 and IL-12 (38, 41–43), was significantly decreased in our model after treatment with FR70. DCs with a reduced expression of these molecules are defined as DCregs or ToldCs (15, 16). Moreover, DCs from the FR70-treated group expressed higher levels of PD-L1 and HO-1, which also promotes the immature and tolerogenic properties of DCs and mediates induction of Tregs. Consistently, the population of CD4^+CD25^+Foxp3^+ cells increased in the treatment group recipients. The observed effects on the number of regulatory cells were moderate but sufficient to restore the immune balance and induce the long-term acceptance of the cardiac allograft. Interestingly, relatively more ToldCs and Tregs were detected in GILs than SPCs, whereas more dramatic effect on CTLs was observed in SPCs.

Recently, Singh et al. published data on mechanism of a long-term islet allografts tolerance in rhesus macaques (44). Adding apoptotic donor leukocytes infusion to short-lived immunosuppression induced a regulatory network characterized by significant and sustained increase in circulating regulatory myeloid, T and B cells, but also qualitative changes in regulatory cells populations with the most prominent role of Tr1 cells (44). Our results also show that, post-treatment time-dependent quantitative and qualitative changes in Tregs and ToldCs in animals treated with FR70 are responsible for long-term tolerogenic effects in transplant survival and tolerogenic memory effect translating into long-term acceptance of grafts also in secondary transplant recipients. However, we cannot exclude effects of FR70 on other CD70-expressing cell populations, such as monocytes or macrophages, or other types of regulatory cells in cardiac acceptance after FR70 treatment.

In conclusion, the FR70 monotherapy showed moderate but pleiotropic effects on different immune cell populations with the induction of the tolerogenic cells populations and affecting the effector cells, which contributed to restoring the immune response to the level observed in the syngeneic model and, in effect, resulted in preventing the allograft rejection. The detailed molecular mechanism underlying the effects of anti-CD70 therapy needs to be further clarified, but modulation of the immune response with anti-CD70 mAb may be considered for the induction of clinical transplantation tolerance and as a strategy for engendering long-term allograft acceptance.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The animal study was reviewed and approved by Committee on the Ethics of Animal Experiments of the National Research Institute for Child Health and Development, Tokyo, Japan.

AUTHOR CONTRIBUTIONS

JZ: Participated in making the research design, performing the research, analyzing the data and writing the article. WQ: Participated in performing the research, analyzing the data. XD: Participated in performing the research, analyzing the data. MF: Participated in making the research design, revising the article for important intellectual content. NI: Participated in making the research design, revising the article for important intellectual content. HU: Participated in making the research design, revising the article for important intellectual content. NT: Participated in making the research design, revising the article for important intellectual content. W-zG: Participated in making the research design, revising the article for important intellectual content. X-KL: Participated in making the research design, revising the article for important intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by research grants from the Grants of Ministry of Education, Culture, Sports, Science and Technology of Japan (Grants-in-Aid 16K11064, 24/17H04277, 18K08558); and grants from the National Center for Child Health and Development.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.555996/full#supplementary-material

Supplementary Figure 1 | The population of central and effector memory T cells in the spleen and graft CD4^+ and CD8^+ T cells on POD7. (A) Grafts were harvested on POD7. The representative data of the CD44 and CD62L staining are presented. The percentage of TCM (CD44^hiCD62L^lo) and TEM (CD44^loCD62L^hi) cells in the CD4^+ and CD8^+ GILs was detected by FCM (n = 4–8 mice for each group, pooled from two independent experiments). Gating strategy is shown in Supplementary Figure 2A. The data are shown as the mean ± SEM, and p < 0.05 was considered significant. (B) Spleens from syngeneic group and allo group were harvested on POD7, and spleens from FR70 group were collected on POD7 and 100. The representative data of the CD44 and CD62L staining are presented. The percentage of TCM (CD44^hiCD62L^lo) and TEM (CD44^loCD62L^hi) cells in the CD4^+ and CD8^+ SPCs was detected by FCM (n = 4–8 mice for each group, pooled from two independent experiments). Gating strategy is shown in Supplementary Figure 2B. The data are shown as the mean ± SEM, and p < 0.05 was considered significant.

Supplementary Figure 2 | Gating strategy for the flow cytometric analysis of lymphocytes from graft and spleen. (A) Gating strategy for lymphocyte analysis in graft. Doublets were discriminated based on SSC-H and SSC-W, and CD45 positive cells were determined in singlets. Next, living cells were gated on CD45^+ cells, and then CD3^+ cells were gated on living cells. Finally, CD3^+ cells were gated for CD4^+ and CD8^+ cells. (B) Gating strategy for lymphocyte analysis in spleen.
Supplementary Figure 3 | Gating strategy for the flow cytometric analysis of DCs (A) and Tregs (B) from graft and spleen. (A) Upper panel: Gating strategy for DC analysis in graft. CD45 positive cells were gated for singlets based on SSC-H and SSC-W, and then living cells were gated on singlets. Then CD3+CD4+ lymphocytes were selected. Finally, further analysis of CD4+ and CD8+ cells on CD3+ cells was performed, and the following phenotypic characteristics were used to define different populations of memory T lymphocytes: CD4+ or CD8+ T EM and T CM, CD44+CD62L− and CD44+CD62L+, respectively.

Supplementary Figure 4 | The mode of action of anti-CD70 mAb in mouse cardiac allograft model. Isootype control treated C3H mice acutely rejected B6 cardiac allografts due to involvement of CD8+ CTLs, while the treatment with anti-CD70 mAb induced long-term allograft acceptance. Blocking CD70/CD27 signaling by using anti-CD70 mAb caused moderate but pleiotropic effects on different immune cell populations by decreasing CTL numbers and the induction of the tolerogenic cells populations, namely TolDCs and Tregs, which contributed to restoring the immune response to the level observed in the syngeneic mouse model and, in effect, resulted in preventing the allograft rejection.

REFERENCES

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant (2011) 11(3):450–62. doi: 10.1111/j.1600-6143.2010.03283.x
2. Yamada A, Sala MD, Sho M, Najafian N, Ito T, Forman JP, et al. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmunization responses in vivo. J Immunol (2005) 174(3):1357–64. doi: 10.4049/jimmunol.174.3.1357
3. Taraban YV, Rowley TF, Al-Shamkani A. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol (2004) 173(11):6542–6. doi: 10.4049/jimmunol.173.11.6542
4. Dai H, Chen J, Shao W, Wang F, Xu S, Peng Y, et al. Blockade of CD27/CD70 signaling by using anti-CD70 mAb caused moderate but pleiotropic effects on different immune cell populations by decreasing CTL numbers and the induction of the tolerogenic cells populations, namely TolDCs and Tregs, which contributed to restoring the immune response to the level observed in the syngeneic mouse model and, in effect, resulted in preventing the allograft rejection.

11. Keller AM, Schildknecht A, Xiao Y, van den Broek AM, Borst J. Expression of CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol (2011) 186(4):195–202. doi: 10.4049/jimmunol.1102002
12. Shao W, Chen J, Dai H, Peng Y, Wang F, Xia J, et al. Combination of monoclonal antibodies with DST inhibits accelerated rejection mediated by memory T cells to induce long-lived heart allograft acceptance in mice. Immunol Lett (2011) 138(2):122–8. doi: 10.1016/j.imlet.2011.03.009
13. Lutz MB, Kurts C. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur J Immunol (2009) 39(9):2325–30. doi: 10.1002/eji.200939548
14. Probst HC, McCoy K, Oka onaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 6(3):280–6. doi: 10.1038/nii.1665
15. Schildknecht A, Miescher I, Yagita H, van den Broek M. Priming of CD8+ T cells by pathogens typically depends on CD70-mediated interactions with dendritic cells. Eur J Immunol (2007) 37(3):716–28. doi: 10.1002/eji.200636824
16. Keller AM, Groothuis TA, Veraa EA, Marsman L, Maquelle de Buy Wenniger L, Janssen H, et al. Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular traffic with MHC class II molecules. Proc Natl Acad Sci USA (2007) 104(14):5989–94. doi: 10.1073/pnas.070946104
17. Van Deusen KE, Rajapakse R, Bullock TN. CD70 expression by dendritic cells plays a critical role in the immunogenecity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses. J Leukoc Biol (2010) 87(3):477–85. doi: 10.1189/jlb.0809535
18. Keller AM, Schildknecht A, Xiao Y, van den Broek AM, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity (2008) 29(6):934–46. doi: 10.1016/j.immuni.2008.10.009
19. Garcia P, De Heredia AB, Bellon T, Carpio E, Llanos M, Caparros E, et al. Signalling via CD70, a member of the TNF family, regulates T cell functions. J Leukoc Biol (2004) 76(1):263–70. doi: 10.1189/jlb.1003508
20. Wang X, Dong C. The CD70-CD27 Axis, a New Brake in the T Helper 17 Cell Response. Immunity (2015) 38(1):1–3. doi: 10.1016/j.immuni.2013.01.005
21. Ahrends T, Babala N, Xiao Y, Yagita H, van Eenuma H, Borst J. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res (2016) 76(10):2921–31. doi: 10.1158/0008-5472.CAN-15-3130
22. Zhao J, Yang XC, Fujino M, Ichimaru N, Que W, Li XK, et al. Salvianolic acid B ameliorates liver injury in a murine aGvHD model by decreasing inflammatory responses via upregulation of HO-1. Transpl Immunol (2011) 24(4):195–202. doi: 10.1016/j.trim.2011.02.002
23. Liu Z, Hou J, Fujino M, Iwasaki S, Hirano H, Cai S, Kitajima Y, et al. Generation and characterization of regulatory dendritic cells derived from murine induced pluripotent stem cells. Sci Rep (2014) 4:3979. doi: 10.1038/srep03979
24. Cai S, Ichimaru N, Zhao M, Fujino M, Ito H, Ota U, et al. Prolonged Mouse Cardiac Graft Cold Storage via Attenuating Ischemia-Reperfusion Injury Using a New Antioxidant-Based Preservation Solution. Transplantation (2016) 100(5):1032–40. doi: 10.1097/TP.0000000000001079
25. Liu Z, Hou J, Chen J, Tsumura H, Ho M, Ho Y, et al. Deletion of CD98 heavy chain in T cells results in cardiac allograft acceptance by increasing regulatory T cells. Transplantation (2012) 93(11):1116–4. doi: 10.1097/TP.0b13e318246f7cd7
26. Hou J, Zhang Q, Fujino M, Cai S, Ito H, Takahashi YK, et al. s-α-Monomeric α-lipoic acid with ferrous iron induces permanent allograft acceptance in mice via induction of regulatory cells. J Heart Lung Transplant (2015) 34(2):254–63. doi: 10.1016/j.healun.2014.09.037
27. Zhang Q, Ichimaru N, Higuchi S, Cai S, Hou J, Fujino M, et al. Permanently acceptance of mouse cardiac allografts with CD40 siRNA to induce regulatory myeloid cells by use of a novel polysaccharide siRNA delivery system. Gene Ther (2015) 22(3):217–26. doi: 10.1038/gt.2014.119
28. Zhao M, Zhu P, Fujino M, Nishida Y, Chen J, Ito H, et al. s-α-Monomeric α-lipoic acid with sodium ferrous citrate induces autophagy and protects cardiomyocytes from hypoxia-induced cellular injury through MAPK-Nrf-2-HO-1 signaling cascade. Biochem Biophys Res Commun (2016) 479(4):663–9. doi: 10.1016/j.bbrc.2016.09.156
29. Zhao J, Yang XC, Fujino M, Ichimaru N, Que W, Li XK, et al. Salvianolic acid B ameliorates liver injury in a murine aGvHD model by decreasing inflammatory responses via upregulation of HO-1. Transpl Immunol (2019). doi: 10.1016/j.trim.2019.03.002
30. Ueta H, Shi C, Miyanari N, Xu XD, Zhou S, Yamashita M, et al. Systemic transmigration of allosensitizing donor dendritic cells to host secondary
lymphoid organs after rat liver transplantation. *Hepatology* (2008) 47 (4):1352–62. doi: 10.1002/hep.22161

28. Miki T, Sun H, Lee Y, Tandin A, Kowseck AM, Subbotin V, et al. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. *Transplant Proc* (2001) 33(1-2):129–30. doi: 10.1016/S0041-1345(00)02792-5

29. Friberg M, Jennings R, Alsaaraj M, Desseureault S, Cantor A, Extermann M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. *Int J Cancer* (2002) 101(2):151–5. doi: 10.1002/jic.10645

30. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. *Science* (2002) 297(5588):1867–70. doi: 10.1126/science.1073514

31. Choi AM, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. *Am J Respir Cell Mol Biol* (1996) 15(1):9–19. doi: 10.1165/ajrcmb.15.1.8679277

32. Katori M, Busuttil RW, Kupiec-Weglinski JW. Heme oxygenase-1 system in lymphoid organs after rat liver transplantation. *Hepatology* (2008) 47(4):1352–62. doi: 10.1002/hep.22161

33. Zahorchak AF, Macedo C, Hamm DE, Butterfield LH, Metes DM, Thomson AW, et al. High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. *Cell Immunol* (2018) 325:9–18. doi: 10.1016/j.cellimm.2017.08.008

34. Mellor AL, Lemos H, Huang L. Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now? *Front Immunol* (2017) 8:1360. doi: 10.3389/fimmu.2017.01360

35. Scroggins SM, Olivier AK, Meyerholz DK, Schluterman AJ. Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation. *PloS One* (2013) 8(9):e75158. doi: 10.1371/journal.pone.0075158

36. Li Q, Guo Z, Xu X, Xia S, Cao X. Pulmonary stromal cells induce the generation of regulatory DC attenuating T-cell-mediated lung inflammation. *Eur J Immunol* (2008) 38(10):2751–61. doi: 10.1002/eji.200838542

37. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. *Cell* (2000) 101(5):455–8. doi: 10.1016/S0092-8674(00)80856-9

38. Ascher NL, Hoffman RA, Hanto DW, Simmons RL. Cellular basis of allograft rejection. *Immunol Rev* (1984) 77:217–32. doi: 10.1111/j.1600-065X.1984.tb00723.x

39. Munitic I, Kuka M, Allam A, Scoville JP, Ashwell JD. CD70 deficiency impairs effector CD8 T cell generation and viral clearance but is dispensable for the recall response to lymphocytic choriomeningitis virus. *J Immunol* (2013) 190 (3):1169–79. doi: 10.4049/jimmunol.1202353

40. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. *Nat Rev Immunol* (2007) 7(8):610–21. doi: 10.1038/nri2132

41. Ahmed EB, Wang T, Daniels M, Alegre ML, Chong AS. IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice. *Am J Transplant* (2011) 11(5):936–46. doi: 10.1111/j.1600-6143.2011.03476.x

42. Rao DA, Eid RE, Qin L, Yi T, Kirkiles-Smith NC, Tellides G, et al. Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. *J Exp Med* (2008) 205(13):3145–58. doi: 10.1084/jem.20081661

43. Minamoto K, Pinsky DJ. Recipient iNOS but not eNOS deficiency reduces luminal narrowing in tracheal allografts. *J Exp Med* (2002) 196(10):1321–33. doi: 10.1084/jem.20012135

44. Singh A, Ramachandran S, Graham ML, Daneshmandi S, Keller D, Suarez-Pinzon WL, et al. Long-term tolerance of islet allografts in nonhuman primates induced by apoptotic donor leukocytes. *Nat Commun* (2019) 10 (1):3495. doi: 10.1038/s41467-019-11338-y

**Conflict of Interest:** PZ was employed by argenx BV. HH holds ownership interest (including patents) in argenx.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhao, Que, Du, Fujino, Ichimaru, Ueta, Tokuda, Guo, Zabrocki, de Haard, Nonomura and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.